In focus · trending topic

MIN-101

17 stories · following the connections

Minerva Neurosciences Reports First Quarter 2018 Financial Results and Business Updates

By Nasdaq OMXMay 3, 2018, 11:30 AM UTC

Minerva Neurosciences to Report Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2018

By Nasdaq OMXMar 5, 2018, 1:31 PM UTC

Minerva Neurosciences Screens First Patient in Phase 3 Trial Of MIN-101 to Treat Negative Symptoms in Schizophrenia

By Nasdaq OMXDec 19, 2017, 1:01 PM UTC

Minerva Neurosciences Reports Second Quarter 2017 Financial Results and Business Updates

By Nasdaq OMXAug 3, 2017, 11:30 AM UTC

American Journal of Psychiatry Publishes Minerva Neurosciences’ MIN-101 Phase 2b Trial Results for Treatment of Negative Symptoms in Schizophrenia

By Nasdaq OMXJul 31, 2017, 12:30 PM UTC

Minerva Announces Outcome of End-of-Phase 2 Meeting With FDA

By Nasdaq OMXMay 15, 2017, 12:01 PM UTC

Minerva Announces Outcome of End-of-Phase 2 Meeting With FDA

By Nasdaq OMXMay 15, 2017, 12:01 PM UTC

Minerva Neurosciences Reports First Quarter 2017 Financial Results and Business Updates

By Nasdaq OMXMay 4, 2017, 11:46 AM UTC